Key Takeaways GE HealthCare unveiled Flyrcado, its FDA-approved PET agent for cardiac imaging, at SNMMI 2025. Flyrcado supports GEHC's growth in precision cardiac care by enabling earlier, more personalized diagnosis. GEHC gained CMS pass-through status and insurer coverage to accelerate Flyrcado's national rollout.GE HealthCare (GEHC) recently unveiled new advancements in precision cardiac care at the 2025 SNMMI annual meeting in New Orleans, with a spotlight on Flyrcado—its FDA-approved Positron Emissio ...